← Back to Clinical Trials
Recruiting NCT06939192

NCT06939192 E-health-supported Diagnostic and Intervention in Preterm Born Children and Their Families

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06939192
Status Recruiting
Phase
Sponsor University Hospital Tuebingen
Condition Preterm Birth
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2024-01-31
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 28 Weeks
Max Age 34 Weeks
Study Type INTERVENTIONAL
Interventions
Intervention Group (APP)Treatment as usual-Group (TAU)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2024-01-31 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The app-based diagnostic and support approach with a focus on mental and somatic symptoms is intended to strengthen the resilience of premature born children and families and to identify risk and resilience factors.The overall objective of the study is to improve the post-inpatient care of families with premature born children. The procedure is evaluated by a two-arm design with an experimental group and a TAU group.

Eligibility Criteria

Inclusion Criteria: * Premature babies born at the UKT, * Gestational age 28-34 weeks, * Mother: age ≥ 18 years, * agreement to participate in this study and signing of a consent form, * sufficient knowledge of German, * internet access Exclusion Criteria: * Premature babies \< 28th or \>34th week of pregnancy, * at least one of the children has serious diseases of the nervous system or obvious symptoms of a nervous disease, * at least one of the children has serious congenital diseases or suffers from malformations, * Mother: Lack of access to a smartphone/tablet, * no internet access, * insufficient knowledge of German

Contact & Investigator

Central Contact

Annette Conzelmann, Prof.Dr.

✉ annette.conzelmann@med.uni-tuebingen.de

📞 00497071/29-87513

Principal Investigator

Annette Conzelmann, Prof. Dr.

PRINCIPAL INVESTIGATOR

Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Tübingen

Frequently Asked Questions

Who can join the NCT06939192 clinical trial?

This trial is open to participants of all sexes, aged 28 Weeks or older, up to 34 Weeks, studying Preterm Birth. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06939192 currently recruiting?

Yes, NCT06939192 is actively recruiting participants. Contact the research team at annette.conzelmann@med.uni-tuebingen.de for enrollment information.

Where is the NCT06939192 trial being conducted?

This trial is being conducted at Tübingen, Germany.

Who is sponsoring the NCT06939192 clinical trial?

NCT06939192 is sponsored by University Hospital Tuebingen. The principal investigator is Annette Conzelmann, Prof. Dr. at Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Tübingen. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology